Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital Medical Center of Ludwig Maximilians University, Munich, Germany.
PLoS One. 2013;8(2):e56194. doi: 10.1371/journal.pone.0056194. Epub 2013 Feb 14.
Folate status, as reflected by red blood cell (RCF) and plasma folates (PF), is related to health and disease risk. Folate degradation products para-aminobenzoylglutamate (pABG) and para-acetamidobenzoylglutamate (apABG) in 24 hour urine have recently been shown to correlate with blood folate.
Since blood sampling and collection of 24 hour urine are cumbersome, we investigated whether the determination of urinary folate catabolites in fasted spot urine is a suitable non-invasive biomarker for folate status in subjects before and during folic acid supplementation.
Immediate effects of oral folic acid bolus intake on urinary folate catabolites were assessed in a short-term pre-study. In the main study we included 53 healthy men. Of these, 29 were selected for a 12 week folic acid supplementation (400 µg). Blood, 24 hour and spot urine were collected at baseline and after 6 and 12 weeks and PF, RCF, urinary apABG and pABG were determined.
Intake of a 400 µg folic acid bolus resulted in immediate increase of urinary catabolites. In the main study pABG and apABG concentrations in spot urine correlated well with their excretion in 24 hour urine. In healthy men consuming habitual diet, pABG showed closer correlation with PF (rs = 0.676) and RCF (rs = 0.649) than apABG (rs = 0.264, ns and 0.543). Supplementation led to significantly increased folate in plasma and red cells as well as elevated urinary folate catabolites, while only pABG correlated significantly with PF (rs = 0.574) after 12 weeks.
Quantification of folate catabolites in fasted spot urine seems suitable as a non-invasive alternative to blood or 24 hour urine analysis for evaluation of folate status in populations consuming habitual diet. In non-steady-state conditions (folic acid supplementation) correlations between folate marker (RCF, PF, urinary catabolites) decrease due to differing kinetics.
红细胞(RCF)和血浆叶酸(PF)反映的叶酸状态与健康和疾病风险有关。最近,24 小时尿液中的叶酸降解产物对氨基苯甲酰谷氨酸(pABG)和对乙酰氨基苯甲酰谷氨酸(apABG)已被证明与血液叶酸相关。
由于血液采样和 24 小时尿液收集繁琐,我们研究了空腹点尿中尿叶酸代谢产物的测定是否适合于叶酸补充前和补充期间受试者的叶酸状态的非侵入性生物标志物。
在短期预研究中评估了口服叶酸丸剂摄入对尿叶酸代谢物的即时影响。在主要研究中,我们纳入了 53 名健康男性。其中,29 名被选为 12 周叶酸补充(400μg)。在基线、6 周和 12 周时采集血液、24 小时尿液和点尿,并测定 PF、RCF、尿 apABG 和 pABG。
摄入 400μg 叶酸丸剂后,尿代谢物立即增加。在主要研究中,点尿中的 pABG 和 apABG 浓度与其 24 小时尿液中的排泄量密切相关。在食用习惯性饮食的健康男性中,pABG 与 PF(rs=0.676)和 RCF(rs=0.649)的相关性优于 apABG(rs=0.264,ns 和 0.543)。补充后,血浆和红细胞中的叶酸以及尿中叶酸代谢物均显著升高,而仅在 12 周后 pABG 与 PF 显著相关(rs=0.574)。
在食用习惯性饮食的人群中,空腹点尿中叶酸代谢物的定量似乎适合作为评估叶酸状态的非侵入性替代方法,替代血液或 24 小时尿液分析。在非稳态条件(叶酸补充)下,由于动力学不同,叶酸标志物(RCF、PF、尿代谢物)之间的相关性降低。